
News|Articles|March 31, 2015
The Impact of CTCs on Survival in Cervical Cancer
Krishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.
Advertisement
Krishnansu S. Tewari, MD, FACOG, FACS, Professor and Director of Research, Principal Investigator, NRG Oncology and GOG Legacy, University of California Irvine, discusses a trial looking at the impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































